Are research peptides legal?

Because "research peptide" is not a legal category. No statute in the European Union or the United Kingdom defines it, grants it a status or exempts it from anything. It is a phrase from the trade. The categories that do exist in law - medicinal product, food, cosmetic, biocide, controlled drug, general chemical - each have their own definitions, and a substance falls into one of them because of facts, not because of what a website calls it.

So the answerable question is narrower and more useful: under what circumstances does a given substance, offered in a given way, meet the definition of a medicinal product? That definition is where nearly all of the legal weight in this category sits, and it is written down and public. The rest of this page is what it says.

Two things this page will not do. It will not tell you that any substance is legal, because that conclusion depends on facts about a transaction that nobody writing a web page can see. And it will not tell you what to do, because that is advice and this is a description of statute.

The definition sits in Directive 2001/83/EC, which together with Regulation (EC) No 726/2004 carries the requirements and procedures for authorising human medicines in the Union. The framework rests on one principle, and the European Commission states it directly: a medicinal product requires a marketing authorisation from the competent authorities before it is placed on the market.

The definition itself has two limbs, and this is the structural point that most discussion of the subject misses. A substance is a medicinal product if it is presented as having properties for treating or preventing disease, or if it may be used in or administered to people with a view to restoring, correcting or modifying physiological functions by pharmacological, immunological or metabolic action, or to making a medical diagnosis. Either limb is enough on its own. They are alternatives, not a two-part test.

A directive is not directly applicable law in a member state; it is transposed into national statute, and enforcement, penalties and practice are national. That is one of the reasons the answer differs by country even though the definition does not.

In materially the same words, because the definition was carried over. Regulation 2 of the Human Medicines Regulations 2012 defines a medicinal product as any substance or combination of substances presented as having properties of preventing or treating disease in human beings, or that may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function through pharmacological, immunological or metabolic action, or making a medical diagnosis.

Two operative rules follow it. Under regulation 46, a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product. Under regulation 279, a person may not publish an advertisement for a medicinal product unless an authorisation is in force for it. The second is why the wording on a page is not a cosmetic question: an advertisement for something with no authorisation is a separate matter from the supply of it, and it can exist without a single sale.

The presentation limb asks how a thing is held out, not what it contains. A substance can meet the definition on presentation alone. The MHRA's borderline guidance and its Guidance Note 8, A guide to what is a medicinal product, set out what is looked at, and the list is longer than most sellers assume:

• every claim made for the product, implicit as well as explicit, including claims on websites, in linked publications, in testimonials and on social media;
• product names, which the guidance treats as capable of carrying an implicit claim on their own;
• the context of the claims and the presentation taken as a whole - how the thing appears to the public it is promoted to;
• labelling, packaging and inserts, including graphics;
• promotional literature and advertising in any medium;
• the product form and the way it is to be used;
• who the marketing is aimed at, in particular groups with, or vulnerable to, a specific condition.

The same guidance lists forms of marketing that in the agency's view may suggest a product is properly classified as a medicine: references to medical conditions, comparison with licensed medicines, references to interference with the normal operation of a physiological function, references to medical or clinical research, recommendations by health professionals, and graphics implying a medicinal use.

Internet material is squarely inside this. Guidance Note 8 states that information on the internet about a product and its uses is not excluded from the definition of an advertisement, and that where a product is sold on or links to a website presenting it as a medicine, the agency will use that website as evidence in the determination. Linking outward to a page that supplies the claim is named as well.

The practical consequence is unpopular but exact: the legal character of a substance can be changed by the copy written next to it. Two vials of identical material, one described by sequence and mass and the other described by what it is said to do, are not necessarily in the same legal category. Nothing about the contents has changed.

The function limb asks what the substance does, and it is decided on the facts of each case rather than by category. Guidance Note 8 builds the current test out of three judgments of the European Court of Justice, which remain the reference point for how the limb is applied:

• HLH Warenvertriebs (C-211/03, 2005) - national authorities must proceed case by case, taking account of all the characteristics of the product: its composition, its pharmacological properties so far as they can be established in the present state of scientific knowledge, the manner of its use, the extent of its distribution, its familiarity to consumers and the risks its use may entail.
• Commission v Germany (C-319/05) - the function definition is designed to cover products whose pharmacological properties have been scientifically observed.
• Hecht-Pharma (C-140/07, 2009) - a product is not a medicinal product by function where, given its composition and used as intended, it is incapable of appreciably restoring, correcting or modifying physiological functions. An effect on the body that does not significantly affect the way the body works is not enough.

Two things follow that matter here. First, the function limb needs observed pharmacological properties, which is a question about evidence and not about intention. Second, "case by case" is not a formula: it means the outcome depends on composition, quantity, presentation, distribution and use in the particular instance, which is precisely the set of facts a general page cannot assess for a reader.

It is a statement of purpose made by a supplier. It is not a licence, not an exemption, and not a category in either the Directive or the Human Medicines Regulations. Nothing in the definition of a medicinal product turns on a supplier's disclaimer as such.

What a research-use statement can do is be one of the facts that make up the presentation of a thing - and the guidance is explicit that presentation is assessed as a whole, in context, including implicit claims and the surrounding website. A page that declares research use in the footer while describing physiological outcomes in the body copy has supplied both facts to the assessment, and the assessment is of the whole. A disclaimer does not cancel a claim made two paragraphs above it.

It is worth noting what the MHRA says about its own guidance. Guidance Note 8 states that it should not be taken as a complete or definitive statement of the law and is not a substitute for legal or other professional advice. If the regulator's published guidance carries that caveat, no commercial website is in a position to do better, including this one.

This site's own position is set out in its research declaration, and it is a description of what the site does rather than a claim about what anyone else may do.

No, and treating it as the only one is a common error. Guidance Note 8 itself describes the interface between the medicines regime and several others: medical devices, cosmetics, biocides, general product safety, food including food supplements, the Misuse of Drugs Act 1971 and the Psychoactive Substances Act 2016. A substance can sit outside the medicines definition and still be caught by another regime entirely.

Alongside those sit obligations that attach to anyone placing a chemical on a market at all - classification, labelling, packaging and safety documentation - and, for anything crossing a border, customs and import rules that are administered nationally and not by a medicines regulator. Each of these is a separate test with its own criteria. Passing one says nothing about the others.

Three reasons, and they compound. The first is transposition: the Directive sets the definition, and twenty-seven member states write it into their own statutes with their own procedures, penalties and enforcement bodies. The second is that the United Kingdom is outside that framework and operates its own, in which the definition survives in the 2012 Regulations but the institutions and remedies are domestic. The third is that enforcement practice differs even where the text does not: what a national agency prioritises, what customs stop, and who may bring an action are national questions.

Germany is a useful illustration of the third. There, advertising for anything presented as having health properties is governed by a dedicated statute and is enforced in large part by competitors through formal warning letters rather than by a regulator, which makes the practical risk faster and likelier than the equivalent elsewhere. The definitional test is the same; the machinery around it is not. The German edition of this site has its own page on that machinery, because a page written for twenty-seven countries cannot do that work honestly.

What can be said is what the sources say:

• The definition of a medicinal product has two independent limbs, presentation and function, and either is sufficient.
• The presentation limb is assessed on the whole context, including implicit claims, product names, and linked websites.
• The function limb requires an appreciable effect on physiological function, judged case by case on all the characteristics of the product.
• A medicinal product requires an authorisation before being placed on the market, in the Union and in the United Kingdom alike.
• Advertising a medicinal product with no authorisation in force is separately prohibited in Great Britain under regulation 279.
• "Research use only" is a statement of purpose, not a legal category, and it is assessed as part of the presentation rather than as an exception to it.

What cannot be said is whether any particular substance, bought by any particular person, in any particular country, for any particular purpose, is lawful. That turns on facts about the substance, the wording of the offer, the jurisdiction and the transaction, and it is a question for a lawyer with those facts in front of them rather than for a website.

Last reviewed: September 2026. This page describes the law as set out in the sources below and is not legal advice.

• Human Medicines Regulations 2012, regulation 2 - the definition of a medicinal product.
• Regulation 46 - unauthorised medicinal products.
• Regulation 279 - advertising a medicinal product.
• MHRA, borderline products - how the agency decides whether a product is a medicine.
• MHRA Guidance Note 8 - the deciding factors under each limb, the case law, and internet advertising.
• European Commission - Directive 2001/83/EC, Regulation (EC) No 726/2004 and the authorisation principle.